Ardelyx Inc Banner Image

Ardelyx Inc

  • Ticker ARDX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Ardelyx Inc Logo Image
  • 51-200 Employees
  • Based in Fremont, California
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndromeMore and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease.
Ardelyx Inc

Most Recent Annual Report

Ardelyx Inc MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Ardelyx Inc has reached its limit for free report views.

Ardelyx Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports